Summary Score in Middle Age Predicts Dementia Status Later in Life
A five question screening tool focusing on middle-age educational and occupational attainment helps predict dementia risk.
AAIC 2015 Coverage
AVP-923 Reduces Agitation in Patients with Alzheimer’s Disease
Currently FDA-approved for treating pseudo bulbar affect, the drug also benefits agitation.
Can Amyloid PET Scans Improve Dementia Outcomes?
The first randomized-controlled clinical trials are underway to assess if early access to amyloid imaging PET scan results can inform treatment decisions for mild cognitive impairment and dementia.
Biogen’s Aducanumab Offers Mixed Results in Alzheimer’s Progression
The big question now is what doses will Biogen examine in aducanumab phase 3 trials.
Investigational Neurotransmitter May Enhance Treatment for Alzheimer’s Symptoms
RVT-101 improved cognition and function when combined with donepezil in patients with mild to moderate Alzheimer’s disease.
Caffeine May Help To Maintain Memory, Inhibit Cognitive Impairment
Greater intake of caffeine among healthy older adults was associated with better memory and executive functioning.
Solanezumab Shows Modest Effect on Alzheimer’s Disease Progression
Investigators identified a possible disease-modifying effect of solanezumab as an early treatment for Alzheimer’s disease, but the benefit in clinical practice remains unclear.
Majority of Dementia Patients Take Multiple Psychotropic Drugs
Dementia patients who were younger, female and lived in nursing homes were most associated with psychotropic polypharmacy.
Memory Decline More Rapid in Women Than Men
Among those with mild cognitive impairment, women’s cognitive abilities deteriorated twice as quickly as men.
New Tool Could Help Better Diagnose Neurocognitive Disorders
Researchers have begun enrolling 800 patients with a neurodegenerative disorder to test the accuracy of the PredictND tool.
Want to read more?
Please login or register first to view this content.
Next post in AAIC 2015 Coverage
